News

GSK falls as blood cancer drug likely headed for US rejection
(Reuters) -GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel ...
STAT1h
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
GSK falls Friday, underperforms market
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
Global Stocks in the Spotlight: Alibaba, Saab, Burberry, GSK
The Swedish defense company posted better-than-expected earnings and [raised its annual sales guidance]( ...
Fierce Biotech2d
GSK telegraphs 'very limited number' of job cuts amid R&D investment spree
With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...
US FDA approves pre-filled version of GSK's shingles vaccine
The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...
Explore more
Fierce Pharma22h
FDA advisors spurn GSK’s Blenrep comeback dreams on safety, trial concerns
On a quest to bring its multiple myeloma antibody-drug conjugate (ADC) Blenrep back to the U.S. | Members of the FDA's Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side ...
GSK's Linerixibat Poised To Address Substantial Unmet Need For The Treatment Of Pruritus Associated With Primary Biliary Cholangitis, According To Spherix Global Insights
Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...